Leukemia, Lymphoblastic, Acute
Conditions
Keywords
Leukemia, Lymphoblastic, Acute
Brief summary
Philadelphia-chromosome-positive or partial ph-like acute lymphoblastic leukemia (ALL) preferred chemotherapy combined with tyrosine kinase inhibitors (TKIS) therapy. Recently we found that there were cytomegalovirus reactivation and even cytomegalovirus infection in three ALL patients treated with chemotherapy combined with TKIs. However, the cytomegalovirus risk after dasatinib use in patients with philadelphia-chromosome-positive ALL is still unknown. It is reported that dasatinib can be observed in the treatment of philadelphia-chromosome-positive leukemia patients with significant increase in large granular lymphocytes, the cytomegalovirus is often positive, and this part of the patient's prognosis is relatively good. Dasatinib can inhibit SRC and TEC kinase, and induce immune function inhibition,and in vitro experiments have confirmed that it inhibits the immune function of T cells and NK cells. In this study, we examined the potential association between cytomegalovirus AND EBV reactivation the treatment of chemotherapy combined with TKIs, and the numbers of large granular cells and NK cell activity.
Interventions
DRUGTKIs
Dasatinib combined with Chematherapy
Sponsors
Nanfang Hospital, Southern Medical University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients diagnosed with acute lymphoblastic leukemia who had not previously received chemotherapy (except for hormone preconditioning) or started with chemotherapy but not more than 3 days, and CMV and EBV quantitative negative; 2. Age Limits:\>or= 14 years old.
Exclusion criteria
1. Patients who had previously received chemotherapy and hematopoietic stem cell transplantation; 2. Patients with CMV and EBV infection before treatment and not to turn yin; 3. The researchers considered unsuitable patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CMV and EBV reactivation rate | 2 years | Evaluation of CMV and EBV reactivation after chemotherapy combined with TKIs therapy in ALL patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The number of large granulosa cells and T、B、NK cell activity | 2 years | Evaluation of the relationship between the number of large granulosa cells and T、B、NK cell activity in patients with CMV positive after TKIs therapy |
Countries
China
Contacts
Primary ContactXutao Guo
Outcome results
None listed